Endpoints for trials in Alzheimer's disease: a European task force consensus (Q37141534)

18 August 2017

1 reference

title

Endpoints for trials in Alzheimer's disease: a European task force consensus (English)

1 reference

18 August 2017

0 references

Nicola Coley

4

0 references

Cristina Sampaio

series ordinal

3

object named as

Cristina Sampaio

1 reference

18 August 2017

1

Bruno Vellas

1 reference

18 August 2017

Sandrine Andrieu

2

1 reference

PubMed ID

18420157

18 August 2017

Gordon Wilcock

series ordinal

5

1 reference

PubMed ID

18420157

18 August 2017

European Task Force Group

series ordinal

6

1 reference

18 August 2017

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

7

1 reference

18 August 2017

436-450

1 reference

18 August 2017

5

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The hunt for drugs to modify Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Transgenic animal models of neurodegenerative diseases and their application to treatment development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Disease-modifying trials in Alzheimer's disease: a European task force consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Forecasting the global burden of Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Designing a large prevention trial: statistical issues.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A randomized trial of vitamin E supplementation and cognitive function in women

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Low dose aspirin and cognitive function in the women's health study cognitive cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A controlled trial of homocysteine lowering and cognitive performance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A randomised controlled trial investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Cognitive performance in relation to vitamin status in healthy elderly German women-the effect of 6-month multivitamin supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Effects of hormone replacement therapy on cognitive performance in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Current concepts in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The Women’s Health Initiative Memory Study (WHIMS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Double placebo design in a prevention trial for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Associations of gait speed and other measures of physical function with cognition in a healthy cohort of elderly persons.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

1 reference

7 January 2021

Primary prevention trials in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Mild cognitive impairment as a diagnostic entity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A neuropsychological test battery for use in Alzheimer disease clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Alzheimer Disease in the US Population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Validity of the Trail Making Test as an Indicator of Organic Brain Damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Functional impairment in instrumental activities of daily living: an early clinical sign of dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Validity and reliability of assessments of time

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Prevention therapeutics of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

ADCS Prevention Instrument Project: overview and initial results.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Alzheimer's disease care: costs and potential savings.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Relatives of the impaired elderly: correlates of feelings of burden.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Measurement of health status. Ascertaining the minimal clinically important difference

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Establishing the Minimal Clinically Important Difference of the Barthel Index in Stroke Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Minimal clinically important change on the unified Parkinson's disease rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970087-5

7 January 2021

10.1016/S1474-4422(08)70087-5

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18420157